This is the second article in the series exploring the major themes emerging from recent efforts to combat the ‘opioid crisis’ and their potential impact on drug manufacturers’ compliance programs. In this article, we explore the pressures facing the DEA to reduce diversion and the possibility of changes to the quota system.
As the opioid epidemic continues to solidify its status as the most prominent contemporary public health issue, the search for a single responsible party continues through a heated finger-pointing debate in Washington. Between a flurry of legislative activity in Congress and a seemingly infinite spool of opioid-related litigation at the federal, state and local levels of government, one might think that the pharmaceutical industry is shouldering the entire burden of the blame; it is not. Competing targets have emerged that include health care providers, pharmacists and even the Drug Enforcement Agency (“DEA”) itself.
To read the full article, visit Life Science Compliance Update.